Highlight 4 in breast cancer
Dr. Elisa Agostinetto, medical oncologist at the Institute Jules Bordet in Brussels shares her highlights from the poster discussion session on local/regional/adjuvant treatment for breast cancer.
She selected two studies emphasising the importance of accurate discrimination of HER2 IHC scores. She also discussed two studies focusing on neoadjuvant treatment. Results from the neoadjuvant I-SPY 2 TRIAL with oral paclitaxel, carboplatin and dostarlimab without and with trastuzumab in early-stage, high-risk breast cancer were discussed.
Dr. Agostinetto concludes with the primary efficacy analyses of NeoRHEA, a neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in ER+/HER2- breast cancer.
With the educational support of:
